Equity intelligence report • May 13, 2026
Bio-Techne Corporation's Q3 2026 results revealed mixed performance with sales of $311.42 million and a net income of $51.05 million, missing market expectations slightly. Adjusted EPS fell to $0.53 while GAAP EPS increased to $0.32. Despite these results, the company is targeting $1.5 billion in revenue by 2028, which necessitates a steady growth rate of 6.5% annually. Analysts maintain a positive outlook on Bio-Techne, indicating significant potential upside based on current stock valuations, even amidst ongoing market fluctuations affecting the sector.
Click a month on the chart to update the report below.
